Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:24:1-5.
doi: 10.1016/j.vhri.2020.07.580. Epub 2020 Dec 19.

Current Development and Practice of Pharmacoeconomic Evaluation Guidelines for Universal Health Coverage in China

Xiaomeng Yue  1 , Yuxiang Li  2 , Jiuhong Wu  3 , Jeff J Guo  4
Affiliations
Free article
Review

Current Development and Practice of Pharmacoeconomic Evaluation Guidelines for Universal Health Coverage in China

Xiaomeng Yue et al. Value Health Reg Issues. 2021 May.
Free article

Abstract

Background: China has achieved near-universal health coverage (UHC) for 95 percent of its population (>1.3 billion lives) as a result of healthcare reforms that began in 2009. However, one of many remaining issues in the Chinese healthcare system is the need to better optimize the allocation and use of healthcare resources in order to meet growing healthcare demands.

Objectives: The goals are to highlight the components of the China Guidelines for Pharmacoeconomic Evaluations (CGPE) 2020 Edition and discuss its future development for UHC in China.

Methods: We review the development process of the CGPE 2020 edition, discuss the contemporary practice of the CGPE for UHC in China, describe new opportunities and challenges to the CGPE, and provide suggestions on the future development of the CGPE based on the current state of the healthcare system in China.

Results: Pharmacoeconomics provides tools to evaluate the health returns and economic costs of pharmaceutical products in a scientific way for the optimal allocation of healthcare resources. Considering the great potential of pharmacoeconomics in China, demonstrated by its rapid development and recognition as a research field in the past decade, the standardization of pharmacoeconomic evaluations has become particularly important to improve the accuracy of evaluation results used for drug selection, price negotiations and adjustments.

Conclusion: Suggestions are made for the integration of CGPE into current framework of UHC in China, including standardizing the pharmacoeconomic evaluation process and updating CGPE on topics such as ethics and real-world research. The CGPE 2020 edition offers a standard to improve the quality of pharmacoeconomic evaluation research and enhance the value and efficiency of UHC in China.

Keywords: guidelines; health technology assessment; healthcare reform; pharmacoeconomic evaluations; universal health coverage.

PubMed Disclaimer

LinkOut - more resources